Baihakke, Norsina S.

HRN: 23-99-19  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/18/2024
CEFTAZIDIME 1GM (VIAL)
09/18/2024
09/25/2024
IV
2g
OD
Sepsis; Cellulitis
Waiting Final Action 

Indication:  Empiric    Type of Infection:  BloodstreamSkin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: